This study examines the updated NCCN Guidelines Insights for Breast Cancer Version 4.2021, focusing on adjuvant systemic therapy recommendations for early-stage, hormone receptor-positive, HER2-negative breast cancer. The guidelines provide nuanced guidance on tailoring treatment regimens to individual patient profiles, integrating factors such as tumor biology and patient comorbidities. By synthesizing evidence from recent clinical trials, the updated guidelines aim to optimize therapeutic outcomes and minimize treatment-related toxicity, thereby enhancing the quality of care for patients with hormone receptor-positive, HER2-negative breast cancer.